Activating Anti-Tumor Immunity

Overcoming immune evasion with innate T cells activated by engineered microbes

Challenges in Cancer Immunotherapy

Cancer’s ability to evade and suppress the immune system continues to limit the effectiveness of modern immunotherapies. Even with breakthroughs like checkpoint inhibitors and engineered T-cell therapies, many high-risk cancers, including AML, soft-tissue sarcomas, and solid tumors, remain resistant to treatment.

Tumors suppress the immune system and evade detection

Most antibody therapies only work for a subset of patients

Cell therapies can be complex and difficult to scale

TARGETING IMMUNE EVASION

The QUAIL Platform

The QUAIL platform was designed to overcome these challenges by activating a powerful innate immune response inside the body. Built on highly attenuated microbial vectors, the platform engages key immune pathways in vivo to drive anti-tumor activity in AML, other high-risk leukemias and soft-tissue sarcomas. By stimulating innate T cell populations and enhancing immune recognition, the QUAIL platform enables robust and durable activation and expansion of endogenous innate T cells .

Engineered microbe

Engineered microbe

Activation of innate T cells

Immune attack on tumors

Immune attack on tumors

Engineered Microbial Platform

The QUAIL Platform is the foundation of a pipeline of highly attenuated microbes that have the predictable PK/PD of small molecule drugs because they cannot grow or survive outside of cells.

Activating Innate T Cells

Laguna’s platforms specifically activate and expand innate T cells including γδ T cells, MAIT cells, and NK T cells. These unconventional T cells are uniquely capable of recognizing and eliminating cancers as well as orchestrating comprehensive immune responses.

In Vivo Immunotherapy

Laguna’s platforms activate immune responses directly inside the body and direct them to target cells. This achieves the ideal goals of in vitro CAR-T therapies without the complexity or risks associated with immune cell engineering.

Engineered Microbial Platform

The QUAIL Platform is the foundation of a pipeline of highly attenuated microbes that have the predictable PK/PD of small molecule drugs because they cannot grow or survive outside of cells.

Activating Innate T Cells

In Vivo Immunotherapy

Engineered Microbial Platform

The QUAIL Platform is the foundation of a pipeline of highly attenuated microbes that have the predictable PK/PD of small molecule drugs because they cannot grow or survive outside of cells.

Activating Innate T Cells

In Vivo Immunotherapy

Engineered Microbial Platform

The QUAIL Platform is the foundation of a pipeline of highly attenuated microbes that have the predictable PK/PD of small molecule drugs because they cannot grow or survive outside of cells.

Activating Innate T Cells

In Vivo Immunotherapy

EVOLVING IMMUNE PRECISION

The IBIS Platform

The IBIS platform is a major evolutionary leap from the QUAIL platform. IBIS strains direct innate T cells to specific tissues enabling precise targeting of specific tumor cells in addition to robust and durable activation and expansion of endogenous innate T cells. The IBIS platform achieves the ideal goals of in vitro CAR-T therapies without the complexity or risks associated with immune cell engineering.

Pipeline

Our pipeline applies the QUAIL and IBIS Platforms across multiple cancer settings

Our Partners

Partner with us on the next frontier

We engineer living medicines that work with biology, not against it, translating microbial intelligence into therapies built to last.

Start the Conversation

Partner with us on the next frontier

We engineer living medicines that work with biology, not against it, translating microbial intelligence into therapies built to last.

Start the Conversation

Partner with us on the next frontier

We engineer living medicines that work with biology, not against it, translating microbial intelligence into therapies built to last.

Start the Conversation